Syn-AKE (Dipeptide Diaminobutyroyl) Peptide

Syn-AKE mimics Waglerin-1 from the temple viper (Tropidolaemus wagleri). It acts as a reversible antagonist at the nicotinic acetylcholine receptor (nAChR) muscular subtype, reducing muscle contraction frequency. Studies report 52% wrinkle reduction after 28 days of topical application.

Syn-AKE (INCI: Dipeptide Diaminobutyroyl Benzylamide Diacetate) is a synthetic tripeptide-like molecule designed by Pentapharm (now DSM) to mimic the muscle-relaxing pharmacology of Waglerin-1, a 22-residue peptide isolated from the venom of the Temple Viper (Tropidolaemus wagleri). Research has focused on its proposed antagonism of the postsynaptic muscle-type nicotinic acetylcholine receptor (nAChR), specifically the ε-subunit-containing isoform expressed at the neuromuscular junction.

Nicotinic Acetylcholine Receptor Antagonism

Waglerin-1 has been characterized as a highly selective, reversible antagonist of the adult muscle nAChR (α1β1εδ subtype), with reported sub-nanomolar affinity for the ε-subunit interface [1]. Syn-AKE was engineered as a small-molecule mimetic that reproduces the key pharmacophore of Waglerin-1 in a fraction of its molecular weight, enabling topical formulation and percutaneous delivery. In preclinical receptor-binding assays, Syn-AKE has been associated with competitive inhibition of acetylcholine binding at the muscle-type nAChR, preventing receptor activation and downstream Na+ influx.

Downstream Effects on Muscle Contraction

By blocking ACh-mediated depolarization at the motor end plate, Syn-AKE research suggests attenuation of the excitation-contraction coupling cascade in skeletal myocytes. In vitro studies on isolated muscle preparations have reported reduced contractile amplitude following Syn-AKE exposure, an effect that has been interpreted as analogous to, though pharmacologically distinct from, the SNARE-protein cleavage mechanism of botulinum neurotoxin type A (BoNT/A).

Comparison to Related Cosmetic Peptides

Syn-AKE is frequently studied alongside Argireline (Acetyl Hexapeptide-8), which inhibits SNAP-25 assembly within the SNARE complex on the presynaptic side, and Leuphasyl (Pentapeptide-18), an enkephalin-like met-enkephalin mimetic that modulates presynaptic ACh release via opioid receptor signaling. Whereas Argireline and Leuphasyl act presynaptically to reduce neurotransmitter release, Syn-AKE acts postsynaptically at the receptor itself. This complementary mechanism has been the basis of multi-peptide cosmetic research combinations.

Cutaneous Penetration Considerations

The dipeptide-benzylamide design lowers molecular weight (<500 Da equivalent for the active fragment) and increases lipophilicity relative to native Waglerin-1, parameters associated with improved stratum corneum penetration under the Lipinski/Bos-Meinardi rules for topical delivery. Vehicle research has examined liposomal, niosomal, and PEG-based carriers to further enhance dermal bioavailability, although Syn-AKE is not intended for systemic exposure in laboratory research contexts.

It is important to note that Syn-AKE is supplied as a research-grade cosmetic raw material and any extrapolation of in vitro receptor data to in vivo dermal outcomes requires controlled experimental validation. All described mechanisms remain investigational.

Syn-AKE is supplied as a research-grade cosmetic raw material, typically as a clear to slightly yellow aqueous solution. The active concentration is most commonly 0.05% w/w of the peptide component (Dipeptide Diaminobutyroyl Benzylamide Diacetate) dispersed in a glycerin/water carrier system with phenoxyethanol as a preservative. Because Syn-AKE is a multi-component cosmetic preparation rather than a single pure peptide, no unified molecular formula, CAS, or MW is assigned to the finished material; each component is characterized individually below.

INCI Designation: Glycerin, Aqua, Dipeptide Diaminobutyroyl Benzylamide Diacetate, Phenoxyethanol (typical declaration order).

Active Peptide Structure: The peptidomimetic active is built around an L-2,4-diaminobutyric acid (Dab) residue conjugated to a benzylamide cap and a β-alanyl-prolyl N-terminal extension, supplied as the diacetate salt. This design captures the key ε-subunit recognition motif of Waglerin-1 in a low molecular weight scaffold suitable for topical research.

Physical Form: Clear, colorless to pale yellow viscous liquid; miscible with water and most polar cosmetic vehicles.

pH (1% solution): Typically 4.5-6.0.

Recommended Use Concentration (research): 4% w/w of the supplied solution in a finished test formulation, delivering approximately 0.002% of the active peptide. Lower concentrations (1-2%) are common in combination peptide formulations.

Purity Statement: The active peptidomimetic component is supplied at ≥98% HPLC purity prior to dilution in the carrier system. A Certificate of Analysis (COA) detailing identity (HPLC, MS) and microbiological specifications is available on request.

Note on CAS Variability: Different manufacturers and salt forms may report alternative CAS numbers for the active peptidomimetic. Researchers should confirm the exact CAS and salt form against the supplied COA before publication.

Syn-AKE is supplied as a topical research solution containing the active dipeptide (β-Ala-Pro-dimethyl-amine, often referenced as Dipeptide Diaminobutyroyl Benzylamide Diacetate) in a stabilised carrier system. Because this is a multi-ingredient cosmetic research preparation rather than a single lyophilised peptide, handling procedures differ from typical injectable peptide protocols.

Recommended Handling Protocol

1. Verify packaging integrity: Inspect the bottle seal, cap, and dropper assembly upon receipt. Any sign of leakage, discoloration, or precipitation should be documented before use in research applications.
2. Allow to reach room temperature: If stored refrigerated, allow the bottle to equilibrate to room temperature (~15-20 minutes) before opening to prevent condensation contamination of the formulation.
3. Use clean dispensing technique: Avoid direct skin contact with the dropper tip. Dispense onto a clean weigh boat, glass slide, or directly onto the dermal research substrate without touching the applicator to test surfaces.
4. Working concentration: Syn-AKE topical solutions are typically supplied at the manufacturer's recommended use concentration (often 4% active peptide content). If further dilution is required for dose-response research, use a compatible aqueous or glycerin-based carrier validated for stability.
5. Single-session aliquoting: For repeated experimental sessions, transfer single-use aliquots to sterile microtubes rather than repeatedly opening the master bottle, minimising oxidative and microbial exposure.
6. Avoid metal contact: Use plastic or glass labware for dilutions and applications. Trace metal ions can catalyse peptide degradation pathways.

Compound-Specific Handling Notes

Light sensitivity: The active dipeptide and accompanying preservatives can show photodegradation. Store and handle in amber glass or opaque containers; minimise bench-top exposure to direct UV or fluorescent light during extended experimental sessions.

Avoid vigorous agitation: Do not vortex aggressively. Gentle inversion or swirling is sufficient to homogenise any settled components. Excessive shaking can introduce air, accelerate oxidation, and foam the formulation.

pH compatibility: The formulation is buffered for dermal compatibility (typically pH 4.5-6.0). Avoid mixing with strongly alkaline or acidic research buffers, which can hydrolyse the active dipeptide or destabilise the carrier system.

Preservative system: Topical research formulations typically contain phenoxyethanol or similar preservatives. Investigators should review the full ingredient declaration before combining with other test articles to identify potential reactivity.

This product is intended exclusively for in vitro and laboratory research applications. It is not formulated, tested, or approved for human use, drug application, or therapeutic purposes.

Proper storage of Syn-AKE topical research solution is essential to maintain the integrity of the active dipeptide component and the surrounding carrier system. Because this is a stabilised aqueous formulation rather than a lyophilised single peptide, storage parameters reflect both peptide chemistry and cosmetic formulation stability principles.

Unopened Bottle Storage

• Long-term (>3 months): Store at 2-8°C (standard laboratory refrigeration) in the original sealed container. Refrigerated storage extends shelf life by slowing hydrolysis of the active dipeptide and maintaining preservative efficacy.
• Short-term (up to 3 months): Storage at controlled room temperature (15-25°C) is acceptable provided the bottle remains sealed and protected from direct light and heat sources.
• Transit conditions: Brief exposure to ambient temperatures (up to 30°C) during shipping does not compromise integrity, as the formulation is designed for cosmetic research distribution stability.

Opened Bottle Storage

• After first opening, refrigerate at 2-8°C and use within 6 months, or sooner if any change in colour, odour, or clarity is observed.
• Always recap tightly immediately after dispensing to limit oxygen and microbial exposure.
• Do not return dispensed aliquots to the master bottle.

Stability Considerations Specific to Syn-AKE

Hydrolytic stability: The active dipeptide contains an amide bond susceptible to slow aqueous hydrolysis. Refrigerated storage at neutral-to-slightly-acidic pH (the formulation's native range) minimises this degradation pathway and preserves potency over the documented shelf life.

Light protection: Although the dipeptide itself is relatively photostable, accompanying excipients and preservatives can undergo UV-induced degradation. Original amber or opaque packaging should be retained, and bottles stored in closed cabinets rather than on illuminated benches.

Avoid freeze-thaw cycles: Unlike lyophilised peptides, this aqueous formulation should not be frozen. Freezing can disrupt the carrier system, precipitate active components, and irreversibly alter the formulation's rheology and bioavailability characteristics in dermal research models.

Microbial integrity: The preservative system is designed for cosmetic shelf life, but improper handling (returning used aliquots, contact between dropper and contaminated surfaces) can overwhelm preservative capacity. Visible turbidity, off-odour, or pH drift indicates the material should be discarded.

For research traceability, investigators should log the date of receipt, date of first opening, and storage conditions. Following these parameters supports reproducible results across extended research timelines.